Calithera Biosciences (NASDAQ:CALA) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Separately, Zacks Investment Research raised Calithera Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Calithera Biosciences currently has an average rating of “Hold” and a consensus price target of $16.50.

Shares of CALA opened at $4.80 on Tuesday. Calithera Biosciences has a fifty-two week low of $4.05 and a fifty-two week high of $18.35. The stock has a market capitalization of $181.74 million, a P/E ratio of -5.83 and a beta of 2.46.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.23. Calithera Biosciences had a negative return on equity of 22.09% and a negative net margin of 90.65%. The company had revenue of $17.07 million during the quarter, compared to analyst estimates of $5.17 million. analysts forecast that Calithera Biosciences will post -1.27 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in CALA. Alps Advisors Inc. grew its holdings in Calithera Biosciences by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 47,583 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 8,270 shares in the last quarter. Citigroup Inc. grew its holdings in Calithera Biosciences by 78.4% during the 1st quarter. Citigroup Inc. now owns 23,746 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 10,433 shares in the last quarter. Trexquant Investment LP grew its holdings in Calithera Biosciences by 25.0% during the 1st quarter. Trexquant Investment LP now owns 59,964 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 12,006 shares in the last quarter. ClariVest Asset Management LLC grew its holdings in Calithera Biosciences by 21.7% during the 1st quarter. ClariVest Asset Management LLC now owns 70,778 shares of the biotechnology company’s stock valued at $445,000 after buying an additional 12,604 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in Calithera Biosciences by 12.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 125,935 shares of the biotechnology company’s stock valued at $794,000 after buying an additional 13,700 shares in the last quarter. 54.85% of the stock is owned by institutional investors.

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Recommended Story: What kind of dividend yield to CEF’s pay?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.